Search

Author/Creator Lee, Jae-Lyun

5. Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. Issue 4 (27th April 2023)

Authors:
Takemura, Kosuke; Navani, Vishal; Ernst, Matthew S.; Wells, J. Connor; Meza, Luis; Pal, Sumanta K.; Lee, Jae-Lyun; Li, Haoran; Agarwal, Neeraj; Alva, Ajjai S.; Hansen, Aaron R.; Basappa, Naveen S.; Szabados, Bernadett; Powles, Thomas; Tran, Ben; Hocking, Christopher M.; Beuselinck, Benoit; Yuasa,...
Journal:
Journal of urology
Issue:
Volume 209:Issue 4(2023)
Page Start:
701
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Issue 12 (December 2020)

Authors:
Powles, Thomas; van der Heijden, Michiel S; Castellano, Daniel; Galsky, Matthew D; Loriot, Yohann; Petrylak, Daniel P; Ogawa, Osamu; Park, Se Hoon; Lee, Jae-Lyun; De Giorgi, Ugo; Bögemann, Martin; Bamias, Aristotelis; Eigl, Bernhard J; Gurney, Howard; Mukherjee, Som D; Fradet, Yves; Skoneczna, Iw...
Journal:
Lancet oncology
Issue:
Volume 21:Issue 12(2020)
Page Start:
1574
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial. Issue 6 (June 2021)

Authors:
Yu, Evan Y; Petrylak, Daniel P; O'Donnell, Peter H; Lee, Jae-Lyun; van der Heijden, Michiel S; Loriot, Yohann; Stein, Mark N; Necchi, Andrea; Kojima, Takahiro; Harrison, Michael R; Hoon Park, Se; Quinn, David I; Heath, Elisabeth I; Rosenberg, Jonathan E; Steinberg, Joyce; Liang, Shang-Ying; Trowb...
Journal:
Lancet oncology
Issue:
Volume 22:Issue 6(2021)
Page Start:
872
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. (September 2016)

Authors:
Ruiz-Morales, Jose Manuel; Swierkowski, Marcin; Wells, J. Connor; Fraccon, Anna Paola; Pasini, Felice; Donskov, Frede; Bjarnason, Georg A.; Lee, Jae-Lyun; Sim, Hao-Wen; Sliwczynsk, Andrzej; Ptak-Chmielewska, Aneta; Teter, Zbigniew; Beuselinck, Benoit; Wood, Lori A.; Yuasa, Takeshi; Pezaro, Carmel...
Journal:
European journal of cancer
Issue:
Volume 65(2016)
Page Start:
102
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression. Issue 3 (14th October 2022)

Authors:
Sternberg, Cora N.; Petrylak, Daniel P.; Bellmunt, Joaquim; Nishiyama, Hiroyuki; Necchi, Andrea; Gurney, Howard; Lee, Jae-Lyun; van der Heijden, Michiel S.; Rosenbaum, Eli; Penel, Nicolas; Pang, See-Tong; Li, Jian-Ri; García del Muro, Xavier; Joly, Florence; Pápai, Zsuzsanna; Bao, Weichao; Elling...
Journal:
Journal of clinical oncology
Issue:
Volume 41:Issue 3(2023)
Page Start:
629
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗